[go: up one dir, main page]

DE602004027824D1 - Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer - Google Patents

Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer

Info

Publication number
DE602004027824D1
DE602004027824D1 DE602004027824T DE602004027824T DE602004027824D1 DE 602004027824 D1 DE602004027824 D1 DE 602004027824D1 DE 602004027824 T DE602004027824 T DE 602004027824T DE 602004027824 T DE602004027824 T DE 602004027824T DE 602004027824 D1 DE602004027824 D1 DE 602004027824D1
Authority
DE
Germany
Prior art keywords
topoisomerase
hemmer
deacetylase inhibitor
histon deacetylase
antitumoral agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027824T
Other languages
English (en)
Inventor
Yoshinori Naoe
Yuka Sasakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of DE602004027824D1 publication Critical patent/DE602004027824D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE602004027824T 2003-09-25 2004-09-24 Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer Expired - Lifetime DE602004027824D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003334340 2003-09-25
JP2003344315 2003-10-02
PCT/JP2004/014451 WO2005030239A2 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor

Publications (1)

Publication Number Publication Date
DE602004027824D1 true DE602004027824D1 (de) 2010-08-05

Family

ID=34380371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027824T Expired - Lifetime DE602004027824D1 (de) 2003-09-25 2004-09-24 Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer

Country Status (14)

Country Link
US (1) US7314862B2 (de)
EP (2) EP1670514B1 (de)
JP (1) JP4779971B2 (de)
AT (1) ATE471740T1 (de)
CA (1) CA2540108A1 (de)
CY (1) CY1114359T1 (de)
DE (1) DE602004027824D1 (de)
DK (1) DK2263694T3 (de)
ES (2) ES2344899T3 (de)
MX (1) MXPA06003222A (de)
PL (2) PL2263694T3 (de)
PT (1) PT2263694E (de)
SI (1) SI2263694T1 (de)
WO (1) WO2005030239A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1426054T3 (da) * 2001-08-21 2011-12-12 Astellas Pharma Inc Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2519320A1 (en) * 2003-02-19 2004-09-02 Astellas Pharma Inc. Method of estimating antitumor effect of histone deacetylase inhibitor
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US7314862B2 (en) 2003-09-25 2008-01-01 Astellas Pharma Inc. Antitumor agent
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1896436A2 (de) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
EP1904452A2 (de) * 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
WO2007040522A1 (en) * 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
JP2009519224A (ja) * 2005-11-18 2009-05-14 グロスター ファーマシューティカルズ， インコーポレイテッド Ｈｄａｃインヒビターｆｋ２２８の代謝産物誘導体
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008013589A2 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101674820B (zh) * 2006-12-26 2013-09-25 药品循环公司 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标志物的方法
MX2009006969A (es) * 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Purificacion de romidepsina.
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
US8034768B2 (en) * 2007-06-22 2011-10-11 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
ES2755909T3 (es) * 2010-07-12 2020-04-24 Celgene Corp Formas sólidas de la romidepsina y sus usos
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CA2845806C (en) 2011-09-13 2019-06-11 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
EP2915536B1 (de) * 2012-11-01 2019-08-21 Microbial Chemistry Research Foundation Antikrebsmittel und kombination mit dem antikrebsmittel
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN116327887B (zh) * 2023-04-24 2023-11-03 南京捷因诊断技术有限公司 一种lsd1抑制剂作为抗肿瘤药物的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486379A (en) * 1892-11-15 Hame-tug
US574455A (en) * 1897-01-05 Switch-lock
US3997633A (en) * 1975-06-24 1976-12-14 Max Leva Contact towers with leak-proof support of improved plate subassembly
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348388A (en) * 1980-04-02 1982-09-07 G.D. Searle & Co. 11-Amino-11-deoxydaunorubicin and analogs
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4950755A (en) * 1985-08-12 1990-08-21 Ohio State University Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane
US5242901A (en) * 1988-01-27 1993-09-07 New York University Reduction of anthracycline induced cardiotoxicity
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5514664A (en) * 1990-05-26 1996-05-07 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridines for application in combatting resistance to drugs
US5620961A (en) * 1994-04-25 1997-04-15 Markovic; Nenad S. Fructose ester-β-cyclodextrin complexes and processes for making and using same
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US6471943B1 (en) * 1996-12-30 2002-10-29 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6286513B1 (en) * 1998-10-22 2001-09-11 Jessie L. Au Methods for treating superficial bladder carcinoma
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
AU783504C (en) * 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
KR20020062956A (ko) * 1999-12-08 2002-07-31 싸이트 테라피스 인코포레이티드 면역억제제로서 사용하기 위한 뎁시펩티드 및 이의 동류물
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
PL366100A1 (en) * 2000-09-22 2005-01-24 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
WO2002024178A2 (en) * 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
AU2002235175A1 (en) * 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
US20030099960A1 (en) * 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
KR20040018341A (ko) * 2001-03-23 2004-03-03 샤이어 바이오켐 인코포레이티드 암치료용 약제 조성물
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
DK1426054T3 (da) * 2001-08-21 2011-12-12 Astellas Pharma Inc Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
JP4773719B2 (ja) * 2002-05-17 2011-09-14 アベンティス・ファーマ・ソシエテ・アノニム 乳癌および卵巣癌のアジュバント療法におけるドセタキセル／ドキソルビシン／シクロホスファミドの使用
AU2003301251A1 (en) * 2002-10-15 2004-05-04 Ferx Incorporated Magnetically guided particles for radiative therapies
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
BRPI0410648A (pt) 2003-05-21 2006-07-04 Novartis Ag combinação de inibidores de histona desacetilase com agentes quimioterápicos
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US7056883B2 (en) * 2003-06-27 2006-06-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US7314862B2 (en) 2003-09-25 2008-01-01 Astellas Pharma Inc. Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
JP4779971B2 (ja) 2011-09-28
EP1670514B1 (de) 2010-06-23
DK2263694T3 (da) 2013-08-26
EP1670514A2 (de) 2006-06-21
CY1114359T1 (el) 2016-08-31
WO2005030239A3 (en) 2005-07-28
CA2540108A1 (en) 2005-04-07
PT2263694E (pt) 2013-08-27
PL2263694T3 (pl) 2013-11-29
US20050070467A1 (en) 2005-03-31
US7314862B2 (en) 2008-01-01
WO2005030239A2 (en) 2005-04-07
EP2263694A1 (de) 2010-12-22
ATE471740T1 (de) 2010-07-15
PL1670514T3 (pl) 2010-11-30
SI2263694T1 (sl) 2013-09-30
ES2344899T3 (es) 2010-09-09
MXPA06003222A (es) 2006-05-22
JP2007506647A (ja) 2007-03-22
ES2425083T3 (es) 2013-10-11
EP2263694B1 (de) 2013-06-12

Similar Documents

Publication Publication Date Title
DE602004027824D1 (de) Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
TW200801006A (en) Fused bicyclic mTOR inhibitors
EA200500859A1 (ru) Хинолинилпирролопиразолы
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
TW200738725A (en) Unsaturated mTOR inhibitors
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
HRP20030831B1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
BRPI0413746A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
TW200504012A (en) Ethynylproline derivatives
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
DK2231633T3 (da) Antitumorale forbindelser